Compare LCNB & BIOA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | LCNB | BIOA |
|---|---|---|
| Founded | 1877 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 267.9M | 255.6M |
| IPO Year | 1999 | 2024 |
| Metric | LCNB | BIOA |
|---|---|---|
| Price | $19.77 | $5.87 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 3 | 10 |
| Target Price | $20.83 | ★ $32.56 |
| AVG Volume (30 Days) | 20.4K | ★ 881.7K |
| Earning Date | 10-15-2026 | 11-09-2026 |
| Dividend Yield | ★ 4.42% | N/A |
| EPS Growth | ★ 68.04 | 66.21 |
| EPS | ★ 0.84 | N/A |
| Revenue | $6,445,000.00 | ★ $8,995,000.00 |
| Revenue This Year | $11.08 | N/A |
| Revenue Next Year | $0.51 | $97.72 |
| P/E Ratio | $23.62 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $14.83 | $4.81 |
| 52 Week High | $21.32 | $25.96 |
| Indicator | LCNB | BIOA |
|---|---|---|
| Relative Strength Index (RSI) | 60.98 | 42.38 |
| Support Level | $18.44 | $4.81 |
| Resistance Level | $20.29 | $8.53 |
| Average True Range (ATR) | 0.51 | 0.39 |
| MACD | 0.11 | 0.21 |
| Stochastic Oscillator | 90.57 | 67.82 |
LCNB Corp operates within the financial sector in the United States. As the holding company of the National Bank, it conducts the business of providing commercial and personal banking services. Its suite of banking products includes commercial and industrial loans, consumer loans, safe deposit boxes, night depositories, cashier's checks, utility bill collections, and notary public service. Besides, it provides the avenue of United States Treasury notes, the United States agency notes, certificates of deposit, and equity securities.
Bioage Labs Inc is a clinical-stage biopharmaceutical company developing therapeutic product candidates for metabolic diseases by targeting the biology of human aging. The company's technology platform and differentiated human datasets enable the identification of targets based on insights into molecular changes that drive aging. The Company operates and manages its business as one reportable and operating segment, which is the business of extending healthy human life by targeting molecular causes of aging.